. .
Sponsor and exhibitor information

Day 2 // Breakout 3:

New developments in

11:30 - Which building blocks will survive the transition from fossil to biobased?

Stefaan de Wildeman


11:50 - Pitches:

Ingo Heschel

Matricel GmbH, DE

Thomas Liénard

Bone Therapeutics. S.A., BE

Florian Coppers

Medical Magnesium, DE

Jean-Manuel Fontaine

12:05 - Plural Polymer Technology for long acting drug development

Jean-Manuel Fontaine

Mithra Pharmaceuticals, BE

Curriculum vitae

Mr. Jean-Manuel Fontaine has 20 years of experience in the pharmaceutical industry in manufacturing, supply chain and commercial positions. He started his career at Pfizer in supply chain and manufacturing where he ensured ERP implementation and integration of Pfizer’s Belgium manufacturing site. In 2001 he joined Lundbeck A/S where he held various positions in sales & marketing in Belgium and France, notably for Cipralex® product. In 2010, Jean-Manuel joined UCB global marketing team to develop the global campaign for the brand and drive business alignment across regions. In 2013, Jean-Manuel joined Mithra to lead successively Business development and Public Relations. Jean-Manuel holds a Master in Pharmaceutical Sciences and MBA from Cornell University.


Many unmet needs remain with the current drug formulations. Polymers can help achieve a controlled release of a given drug or/and a targeted delivery and improved drug bioavailability, which in turn can lead to important societal benefits with a better patient compliance, tolerability and safety and contribute overall to lower healthcare costs. Polymer Technology offers a wide range of opportunities in drug delivery development for multiple therapeutic fields. Mithra Pharmaceuticals has developed over the last 17 years significant experience in long acting drug development (Intra uterine systems, implants, biocompatible rings) for multiple active ingredient families. Mithra is setting-up an integrated R&D and manufacturing platform  in Liège ( Mithra CDMO) , operational by 2017. This site will operate as a pharmaceutical ecosystem where third parties (research centers, academia or life science related industries) can  leverage Mithra’s know-how in long-acting drug development and sterile injectables

12:25 - Pitches:

Sol Cabrera

Eindhoven University of Technology, NL

← back to program